Auf dieser Seite
DCTH Delcath Systems, Inc. - Common Stock
NASDAQ · Health Care · Auf SEC EDGAR ansehen ↗ Schließen Okt 2, 2026 10-K/10-Q Aug 6, 2026
$15,13
· % der 52-Wochen-Spanne
· über Tiefststand
· zu hoch
$8,1252-Wochen-Tief
$17,4252-Wochen-Hoch
Marktkapitalisierung (MRQ)
$524M
P/E (TTM)
1513.0
EPS (TTM)
$0.01
Umsatz (TTM)
$95M
Ihre Abzeichen
52W-Spanne
$8–$17
Analystenbewertung
BUY
Kursziel
$24
P/E
1513.0
ROE
0.47%
Nettogewinnmarge
0.56%
Ihre Abzeichenleiste ist leer – heften Sie eine Kennzahl auf dieser Seite an.
DCTH Aktien-Snapshot Kurs, Marktkapitalisierung, P/E, EPS, ROE, Schulden/Eigenkapital, 52-Wochen-Spanne
Kurs
$15.13
Marktkapitalisierung (MRQ)
$524M
P/E (TTM)
1513.0
EPS (TTM)
$0.01
Umsatz (TTM)
$95M
ROE (TTM)
0.47%
52W-Spanne
$8–$17
DCTH Aktienkurs-Chart Täglich OHLCV mit technischen Indikatoren — Schwenken, Zoom und Ansicht anpassen
Spanne
Balken
Die Balkengranularität passt sich der ausgewählten Periode an – bewegen Sie den Mauszeiger über das Diagramm, um Eröffnungs-/Höchst-/Tiefst-/Schlusskurse für einen Balken anzuzeigen.
Aktiensplits
| Ex-Datum | Split | Typ |
|---|---|---|
| 24. Dezember 2019 | 1-for-700 | Umgekehrt |
Über Delcath Systems, Inc. - Common Stock Unternehmensübersicht von Wikipedia
Delcath Systems, Inc. (NASDAQ: DCTH) is a publicly traded specialty pharmaceutical and medical device company, that develops percutaneous perfusion technologies for the targeted administration of high-dose chemotherapeutic agents to specific organs or regions of the body. Based in Queensbury, New York, the company has an intellectual property portfolio consisting of 28 patents worldwide. Delcath's Percutaneous Hepatic Perfusion (PHP) is currently undergoing Phase II and Phase III trials against tumors in the liver. Delcath has a Cooperative Research and Development Agreement (CRADA) with the National Cancer Institute and has received Fast Track and a Special Protocol Assessment from the Food and Drug Administration for its use of melphalan in treating unresectable liver tumors. PHP, also known as the Delcath System, is tested for the treatment of metastatic melanoma in the liver and for primary liver cancer and metastatic hepatic malignancies from neuroendocrine cancers and adenocarcinomas, as well as patients with melanoma who previously received isolated perfusion. Chemotherapy is usually delivered intravenously, although a number of agents can be administered orally (e.g. specialty drugs, melphalan (trade name Alkeran), busulfan, capecitabine).
## Phase III melanoma trial enrolling
University of Pittsburgh Medical Center
National Cancer Institute in Bethesda, Maryland
Albany Medical Center in Albany, New York
John Wayne Cancer Center in Santa Monica, California
Moffitt Cancer Center in Tampa, Florida
Morristown Memorial Hospital in Morristown, New Jersey
Providence Cancer Center in Portland, Oregon
St. Luke's Cancer Center of Bethlehem, Pennsylvania
Swedish Medical Center in Englewood, Colorado
University of Maryland Medical Center in Baltimore, Maryland
University of Texas Medical Branch in Galveston, Texas
Quelle: Wikipedia (Englisch), CC BY-SA 4.0 · Auf Wikipedia ansehen ↗
SektorHealth Care
BrancheHealth Care
Mitarbeiter156
LandUS
10-Jahres-Performance Umsatz-, Nettoergebnis-, Margen- und EPS-Trends
Umsatz$85M2016-12-31 → 2025-12-31
EPS$0.072017-12-31 → 2025-12-31
Freier Cashflow$21M2018-12-31 → 2025-12-31
Nettogewinnmarge0.56%2022-12-31 → 2025-12-31
Bewertung & Kennzahlen
Bewertung P/E-, P/S-, P/B-, EV/EBITDA-Verhältnisse — ist die Aktie teuer oder günstig?
| Kennzahl | 5-Jahres-Trend | DCTH | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| P/E (TTM) | 1513.05-Jahres-Durchschnitt ≈25.4 | ≈25.4 | · | · | |
| P/S (TTM) | 5.55-Jahres-Durchschnitt ≈17.7 | ≈17.7 | 3.7 | Überbewertet | |
| K/B (MRQ) | 4.35-Jahres-Durchschnitt ≈3.0 | ≈3.0 | 3.4 | Überbewertet | |
| Kurs / FCF (TTM) | 29.95-Jahres-Durchschnitt ≈-2.2 | ≈-2.2 | · | · | |
| Kurs / Cashflow (TTM) | 26.85-Jahres-Durchschnitt ≈-2.5 | ≈-2.5 | 18.5 | Unterbewertet | |
| Price / Tangible Book (Kurs / Materieller Buchwert) | 4.75-Jahres-Durchschnitt ≈5.0 | ≈5.0 | · | · |
Der Median der Vergleichsgruppe wird pro Kennzahl standardisiert berechnet und stimmt möglicherweise nicht immer mit der für diese Aktie angezeigten TTM/MRQ-Basis überein.
Rentabilität Brutto-, Betriebs- und Nettomargen; ROE, ROA, ROIC
| Kennzahl | 5-Jahres-Trend | DCTH | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Bruttogewinnmarge (TTM) | 87.1%5-Jahres-Durchschnitt ≈78.4% | ≈78.4% | 73.6% | Spitzenklasse | |
| Betriebsgewinnmarge (TTM) | -1.9%5-Jahres-Durchschnitt ≈-781.7% | ≈-781.7% | -8.2% | Spitzenklasse | |
| EBITDA Margin (EBITDA-Marge) | 0.77%5-Jahres-Durchschnitt ≈-781.7% | ≈-781.7% | -5.0% | Spitzenklasse | |
| Vorgewinnmarge (TTM) | 1.4%5-Jahres-Durchschnitt ≈-929.6% | ≈-929.6% | -11.3% | Spitzenklasse | |
| Nettogewinnmarge (TTM) | 0.56%5-Jahres-Durchschnitt ≈-929.8% | ≈-929.8% | -13.1% | Spitzenklasse | |
| ROA (TTM) | 0.42%5-Jahres-Durchschnitt ≈-86.2% | ≈-86.2% | -16.0% | Spitzenklasse | |
| ROE (TTM) | 0.47%5-Jahres-Durchschnitt ≈27.9% | ≈27.9% | -25.7% | Spitzenklasse | |
| ROIC | 0.46%5-Jahres-Durchschnitt ≈22.6% | ≈22.6% | -23.7% | Spitzenklasse |
Finanzielle Gesundheit Verschuldung, Liquidität, Solvenz — Bilanzstärke
| Kennzahl | 5-Jahres-Trend | DCTH | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Liquiditätsgrad (MRQ) | 9.85-Jahres-Durchschnitt ≈6.3 | ≈6.3 | 3.5 | Starke Liquidität | |
| Quick Ratio | 5.05-Jahres-Durchschnitt ≈3.5 | ≈3.5 | 2.2 | Starke Liquidität |
Wachstum Umsatz-, EPS- und Nettoergebniswachstum: YoY, 3-Jahres-CAGR, 5-Jahres-CAGR
| Kennzahl | 5-Jahres-Trend | DCTH | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Revenue YoY (Umsatz YoY) | 129.1%5-Jahres-Durchschnitt ≈445.8% | ≈445.8% | · | · | |
| Revenue CAGR 3Y (Umsatz CAGR 3J) | 215.3% | · | · | · |
Kapitaleffizienz Umsatz pro Vermögenswert, Lagerumschlag, Forderungsumschlag
| Kennzahl | 5-Jahres-Trend | DCTH | 5-Jahres-Durchschnitt | Peer-Median | Fazit |
|---|---|---|---|---|---|
| Asset Turnover (Umsatz / Vermögenswerte) | 0.95-Jahres-Durchschnitt ≈0.4 | ≈0.4 | 0.8 | Im Einklang | |
| Inventory Turnover (Lagerumschlag) | 1.45-Jahres-Durchschnitt ≈0.8 | ≈0.8 | 1.7 | Schwach | |
| Receivables Turnover (Forderungsumschlag) | 7.55-Jahres-Durchschnitt ≈8.6 | ≈8.6 | 7.3 | Spitzenklasse | |
| Revenue / Employee (Umsatz / Mitarbeiter) | ≈$546.4K | · | · | · |
Wert · ≈ 5-Jahres-Durchschnitt · Branchenmedian · Urteil relativ zum Median
Ergebnisverlauf EPS Ist vs. Schätzung, Überraschung %, Beat-Rate, nächstes Ergebnisdatum
Durchschn. Überraschung
88.6%
Nächster Bericht
Nov 02, 2026
| Zeitraum | Bericht | EPS Actual | EPS est. | Überraschung |
|---|---|---|---|---|
| 30. Juni 2026 | Aug 10, 2026 | $0.07 | $-0.09 | 176.3% |
| 31. März 2026 | Mai 12, 2026 | $-0.03 | $-0.09 | 66.1% |
| 31. Dezember 2025 | $-0.05 | $-0.06 | 20.5% | |
| 30. September 2025 | $0.02 | $0.02 | -2.0% | |
| 30. Juni 2025 | $0.07 | $0.03 | 174.5% | |
| 31. März 2025 | $0.03 | $0.02 | 96.1% |
Vollständige Fundamentaldaten Alle Kennzahlen nach Jahr — Gewinn- und Verlustrechnung, Bilanz, Cashflow
Gewinn- und Verlustrechnung
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $85M | $37M | $2M | $3M | $4M | · | · | · | $3M | $2M | $2M | $1M | |
| Cost of Revenue | $12M | $6M | $635.0K | $686.0K | $671.0K | $640.0K | $719.0K | $1M | $701.0K | $550.0K | $462.0K | $291.0K | |
| Gross Profit | $73M | $31M | $1M | $2M | $3M | $1M | $861.0K | $2M | $2M | $1M | $1M | $778.0K | |
| R&D Expense | $29M | $14M | $18M | $19M | $14M | $11M | $9M | $20M | $10M | $8M | $6M | $4M | |
| SG&A Expense | $44M | $30M | $22M | $17M | $14M | $11M | $11M | $10M | $10M | $9M | $10M | $16M | |
| Operating Expenses | $73M | $43M | $40M | $36M | $27M | $22M | $21M | $29M | $20M | $18M | $16M | $20M | |
| Operating Income | $660.0K | $-12M | $-38M | $-34M | $-25M | $-21M | $-20M | $-27M | $-18M | $-16M | $-15M | $-19M | |
| Interest Expense | · | · | · | · | · | · | · | · | $22M | $14M | $67.0K | · | |
| Interest Income | · | · | · | · | · | · | · | · | · | $17.0K | $9.0K | $5.0K | |
| Other Non-op | $-70.0K | $-30.0K | $-59.0K | $30.0K | $68.0K | $154.0K | $2.0K | $51.0K | $-41.0K | $17.0K | $9.0K | $-24.0K | |
| Pretax Income | $4M | $-26M | $-48M | $-37M | $-26M | $-24M | $-9M | $-19M | $-45M | $-18M | $-15M | $-17M | |
| Income Tax | $810.0K | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| Net Income | $3M | $-26M | $-48M | $-37M | $-26M | $-24M | $-9M | $-19M | $-45M | $-18M | $-15M | $-17M | |
| EPS (Basic) | $0.08 | $-0.93 | $-2.94 | $-4.12 | $-3.59 | $-8.35 | $-342.83 | $-0.72 | $-3250.00 | · | $-0.91 | $-1.84 | |
| EPS (Diluted) | $0.07 | $-0.93 | $-2.94 | $-4.12 | $-3.59 | $-8.35 | $-342.83 | $-0.72 | $-3250.00 | · | $-0.91 | $-1.84 | |
| Shares (Basic) | 35,821,157 | 28,511,393 | 16,229,931 | 8,864,615 | 7,145,754 | 2,897,827 | 25,900 | 26,705,375 | 14,039 | · | 16,161,687 | 9,452,050 | |
| Shares (Diluted) | 39,919,557 | 28,511,393 | 16,229,931 | 8,864,615 | 7,145,754 | 2,897,827 | 25,900 | 26,705,375 | 14,039 | · | 16,161,687 | 9,452,050 | |
| EBITDA | $660.0K | $-12M | $-38M | $-34M | $-25M | $-21M | $-20M | $-27M | · | · | $-15M | $-19M |
Bilanz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $43M | $32M | $13M | $8M | $23M | $29M | $10M | $3M | $4M | $4M | $13M | $20M | |
| Receivables | $12M | $11M | $241.0K | $366.0K | $44.0K | $57.0K | $21.0K | $585.0K | $317.0K | $403.0K | $277.0K | $174.0K | |
| Inventory | $10M | $7M | $3M | $2M | $1M | $855.0K | $654.0K | $858.0K | $1M | $660.0K | $757.0K | $349.0K | |
| Prepaid Expense | $6M | $3M | $1M | $2M | $3M | $3M | $2M | $898.0K | $700.0K | $698.0K | $960.0K | $974.0K | |
| Other Current Assets | · | · | · | · | · | · | · | · | · | · | · | $222.0K | |
| Current Assets | $120M | $74M | $37M | $16M | $31M | $32M | $13M | $6M | $8M | $34M | $15M | $22M | |
| PP&E (Net) | $3M | $2M | $1M | $1M | $1M | $1M | $735.0K | $925.0K | $1M | $1M | $1M | $2M | |
| PP&E (Gross) | $8M | $7M | $6M | $6M | $6M | $6M | $5M | $5M | $5M | $5M | $5M | $6M | |
| Accum. Depreciation | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $4M | $4M | $4M | $4M | $4M | |
| Total Assets | $124M | $77M | $39M | $18M | $33M | $35M | $14M | $7M | $9M | $35M | $16M | $24M | |
| Accounts Payable | $3M | $961.0K | $1M | $2M | $638.0K | $2M | $5M | $8M | $4M | $594.0K | $284.0K | $748.0K | |
| Accrued Liabilities | $8M | $5M | $5M | $5M | $4M | $5M | $7M | $8M | $3M | $3M | $2M | $4M | |
| Current Liabilities | $11M | $6M | $16M | $15M | $6M | $10M | $16M | $18M | $8M | $36M | $6M | $5M | |
| Capital Leases | $835.0K | $933.0K | $0 | · | $207.0K | $450.0K | $197.0K | $0 | · | · | · | · | |
| Other Non-current Liabilities | $628.0K | $766.0K | $840.0K | $1M | $207.0K | · | $0 | $628.0K | $395.0K | $604.0K | $820.0K | $1M | |
| Total Liabilities | $12M | $8M | $23M | $24M | $21M | $13M | $21M | $22M | $8M | $37M | $7M | $6M | |
| Long-term Debt | · | $0 | $10M | $16M | · | · | · | · | · | · | · | · | |
| Common Stock | $347.0K | $331.0K | $228.0K | $100.0K | $79.0K | $60.0K | $1.0K | $0 | $2.0K | $0 | $14.0K | $97.0K | |
| Paid-in Capital | $639M | $600M | $521M | $452M | $433M | $417M | $365M | $329M | $326M | $278M | $270M | $265M | |
| Retained Earnings | $-529M | $-532M | $-505M | $-457M | $-421M | $-395M | $-371M | $-344M | $-325M | $-279M | $-261M | $-247M | |
| Treasury Stock | · | · | · | · | · | · | · | $0 | $51.0K | $51.0K | $51.0K | $51.0K | |
| AOCI | $575.0K | $82.0K | $135.0K | $-83.0K | $18.0K | $-104.0K | $28.0K | $50.0K | $42.0K | $-41.0K | $-8.0K | $20.0K | |
| Stockholders' Equity | $111M | $69M | $16M | $-6M | $12M | $22M | $-6M | $-15M | $678.0K | $-1M | $9M | $18M | |
| Liabilities + Equity | $124M | $77M | $39M | $18M | $33M | $35M | $14M | $7M | $9M | $35M | $16M | $24M | |
| Shares Outstanding | 34,691,671 | 33,061,002 | 22,761,554 | 10,046,571 | 7,906,728 | 5,996,101 | 67,091 | 14,715 | 228,139 | 11,750 | 1,360,239 | 9,708,841 |
Cashflow
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Deferred Tax | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| Operating Cash Flow | $23M | $-19M | $-31M | $-25M | $-23M | $-23M | $-24M | $-15M | $-15M | $-14M | $-16M | $-16M | |
| CapEx | $2M | $559.0K | $58.0K | $209.0K | $143.0K | $782.0K | $24.0K | $76.0K | $524.0K | $258.0K | $170.0K | $44.0K | |
| Investing Cash Flow | $-27M | $-981.0K | $-20M | $-209.0K | $-143.0K | $-782.0K | $-24.0K | $-76.0K | $-524.0K | · | · | · | |
| Net Debt Issued | · | $-11M | $-6M | · | · | · | · | · | · | · | · | · | |
| Stock Issued | $481.0K | $250.0K | $123.0K | $0 | $2M | $230.0K | $0 | $11M | · | · | · | · | |
| Stock Repurchased | $6M | $0 | · | · | · | · | · | · | · | · | · | · | |
| Net Stock Activity | $-6M | $250.0K | $123.0K | · | $2M | $230.0K | $0 | · | · | · | · | · | |
| Financing Cash Flow | $15M | $39M | $52M | $10M | $21M | $42M | $30M | $13M | $-11M | · | · | · | |
| Net Change in Cash | $11M | $20M | $874.0K | $-15M | $-2M | $19M | $7M | $-2M | $-26M | $-8M | $-8M | $-11M | |
| Taxes Paid | $2M | $0 | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $21M | $-19M | $-31M | $-25M | $-23M | $-24M | $-24M | $-15M | · | · | $-17M | $-16M |
Rentabilität
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 86.2% | 83.4% | 69.2% | 74.8% | · | · | · | · | · | · | 73.6% | 72.8% | |
| Operating Margin | 0.77% | -33.4% | -1849.0% | -1245.0% | · | · | · | · | · | · | -870.6% | -1805.8% | |
| Net Margin | 3.2% | -70.9% | -2308.9% | -1342.7% | · | · | · | · | · | · | -841.7% | -1625.9% | |
| Pretax Margin | 4.1% | -70.9% | -2308.9% | -1342.7% | · | · | · | · | · | · | -841.7% | · | |
| EBITDA Margin | 0.77% | -33.4% | -1849.0% | -1245.0% | · | · | · | · | · | · | -870.6% | -1805.8% | |
| ROA | 2.7% | -45.8% | -168.8% | -143.2% | -75.7% | -98.9% | -84.3% | -244.4% | · | · | -74.5% | -57.1% | |
| ROE | 2.5% | -68.2% | -235.5% | 657.5% | -216.7% | -190.6% | 70.5% | 194.1% | · | · | -109.9% | -72.0% | |
| ROIC | 0.46% | -18.1% | -242.0% | 577.8% | -205.3% | -96.5% | 313.2% | · | · | · | -176.8% | · |
Liquidität & Solvenz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.9 | 12.0 | 2.3 | 1.1 | 5.2 | 3.2 | 0.8 | 0.3 | · | · | 2.3 | 4.8 | |
| Quick Ratio | 5.0 | 7.0 | 0.8 | 0.5 | 3.8 | 2.9 | 0.6 | 0.2 | · | · | 2.0 | 4.5 |
Effizienz
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.9 | 0.6 | 0.1 | 0.1 | · | · | · | · | · | · | 0.1 | 0.0 | |
| Inventory Turnover | 1.4 | 1.2 | 0.2 | 0.4 | 0.6 | 0.8 | 1.0 | 1.0 | · | · | 0.8 | 0.5 | |
| Receivables Turnover | 7.5 | 6.7 | 6.8 | 13.3 | · | · | · | · | · | · | 7.7 | 4.1 |
Pro Aktie
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $3.21 | $2.08 | $0.69 | $-0.74 | $1.51 | $3.68 | $-94.75 | $-1.46 | · | · | $0.40 | $1.87 | |
| Revenue / Share | $2.14 | $1.30 | $0.13 | $0.31 | · | · | · | · | · | · | $0.11 | $0.11 | |
| Cash Flow / Share | $0.56 | $-0.66 | $-1.93 | $-2.81 | · | $-7.89 | · | $-0.55 | · | · | $-1.02 | $-1.65 | |
| Cash / Share | $1.25 | $0.98 | $0.56 | $0.97 | $2.88 | $4.77 | $149.08 | $0.25 | · | · | $0.58 | $2.11 | |
| EPS (TTM) | $0.07 | $-0.93 | $-2.94 | $-4.12 | $-3.59 | $-8.35 | $-342.83 | $-0.72 | $-3250.00 | · | $-0.91 | $-1.84 |
Wachstumsraten
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 129.1% | 1701.7% | -24.1% | -23.5% | · | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 215.3% | 118.7% | · | · | · | · | · | · | · | · | · | · |
Bewertung (TTM)
| Kennzahl | Trend | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $85M | $37M | $2M | $3M | $4M | $3M | $3M | $3M | $3M | $2M | $2M | $1M | |
| Net Income TTM | $3M | $-26M | $-48M | $-37M | $-26M | $-24M | $-9M | $-19M | $-45M | $-18M | $-15M | $-17M | |
| Market Cap | $350M | $398M | $95M | $28M | $61M | $107M | $1M | $2.01B | · | · | · | · | |
| P/E | 144.3 | -12.9 | -1.4 | -0.9 | -2.2 | -2.1 | -0.1 | -272.2 | · | · | · | · | |
| P/S | 4.1 | 10.7 | 45.9 | 10.5 | 17.2 | 34.8 | 0.5 | 649.3 | · | · | · | · | |
| P/B | 3.2 | 5.8 | 6.0 | -4.9 | 5.1 | 4.9 | -0.2 | -134.2 | · | · | · | · | |
| P / Tangible Book | 3.2 | 5.8 | 6.0 | · | 5.1 | 4.9 | · | · | · | · | · | · | |
| P / Cash Flow | 15.6 | -21.3 | -3.0 | -1.1 | -2.7 | -4.7 | -0.1 | -136.1 | · | · | · | · | |
| P / FCF | 16.7 | -20.7 | -3.0 | -1.1 | -2.7 | -4.5 | -0.1 | -135.4 | · | · | · | · | |
| Earnings Yield | 0.69% | -7.7% | -70.7% | -114.4% | -46.3% | -46.6% | -1613.3% | -0.37% | · | · | · | · |
Gewinn- und Verlustrechnung
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $29M | $25M | $21M | $21M | $24M | $20M | $15M | $11M | $8M | $3M | $539.0K | $434.0K | $495.0K | $597.0K | $638.0K | $906.0K | |
| Cost of Revenue | $3M | $4M | $3M | $3M | $3M | $3M | $2M | $2M | $2M | $903.0K | $171.0K | $133.0K | $150.0K | $181.0K | $238.0K | $235.0K | |
| Gross Profit | $26M | $21M | $18M | $18M | $21M | $17M | $13M | $10M | $6M | $2M | $368.0K | $301.0K | $345.0K | $416.0K | $400.0K | $671.0K | |
| R&D Expense | $10M | $10M | $9M | $8M | $7M | $5M | $3M | $4M | $3M | $4M | $5M | $5M | $4M | $5M | $4M | $4M | |
| SG&A Expense | $13M | $13M | $11M | $10M | $11M | $11M | $7M | $7M | $7M | $9M | $7M | $6M | $5M | $4M | $4M | $5M | |
| Operating Expenses | $24M | $23M | $20M | $18M | $18M | $16M | $10M | $11M | $10M | $13M | $12M | $11M | $8M | $9M | $8M | $9M | |
| Operating Income | $2M | $-2M | $-2M | $-388.0K | $3M | $642.0K | $3M | $-1M | $-4M | $-10M | $-11M | $-11M | $-8M | $-8M | $-8M | $-8M | |
| Other Non-op | $-17.0K | $-58.0K | $-7.0K | $-33.0K | $-34.0K | $4.0K | $-53.0K | $35.0K | $10.0K | $-22.0K | $-73.0K | $-5.0K | $6.0K | $13.0K | $27.0K | $26.0K | |
| Pretax Income | $3M | $-908.0K | $-1M | $375.0K | $3M | $1M | $-3M | $2M | $-14M | $-11M | · | · | · | · | · | · | |
| Income Tax | $491.0K | $162.0K | $562.0K | $-455.0K | $508.0K | $195.0K | $0 | $0 | $0 | $0 | · | · | · | · | · | · | |
| Net Income | $3M | $-1M | $-2M | $830.0K | $3M | $1M | $-3M | $2M | $-14M | $-11M | $-11M | $-20M | $-7M | $-9M | $-8M | $-9M | |
| EPS (Basic) | $0.07 | $-0.03 | $-0.05 | $0.02 | $0.08 | $0.03 | $-0.06 | $0.06 | $-0.48 | $-0.45 | $-0.45 | $-1.14 | $-0.58 | $-0.77 | $-0.82 | $-0.96 | |
| EPS (Diluted) | $0.07 | $-0.03 | $-0.05 | $0.02 | $0.07 | $0.03 | $-0.06 | $0.06 | $-0.48 | $-0.45 | $-0.45 | $-1.14 | $-0.58 | $-0.77 | $-0.82 | $-0.96 | |
| Shares (Basic) | 35,891,915 | 36,021,210 | · | 36,383,277 | 35,786,813 | 34,642,641 | · | 28,738,307 | 28,364,731 | 24,887,180 | · | 17,863,078 | 12,463,665 | 11,622,384 | · | 9,215,786 | |
| Shares (Diluted) | 39,761,480 | 36,021,210 | · | 40,056,814 | 40,262,764 | 39,511,120 | · | 32,345,672 | 28,364,731 | 24,887,180 | · | 17,863,078 | 12,463,665 | 11,622,384 | · | 9,215,786 | |
| EBITDA | $2M | $-2M | · | $-388.0K | $3M | $642.0K | · | $-1M | $-4M | $-10M | · | $-11M | $-8M | $-8M | · | $-8M |
Bilanz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $48M | $41M | $43M | $42M | $34M | $13M | $32M | $8M | $15M | $12M | $13M | $40M | $15M | $24M | $8M | $10M | |
| Receivables | $16M | $14M | $12M | $14M | $16M | $14M | $11M | $7M | $4M | $2M | $241.0K | $205.0K | $127.0K | $458.0K | $366.0K | $537.0K | |
| Inventory | $12M | $10M | $10M | $11M | $11M | $7M | $7M | $7M | $6M | $4M | $3M | $3M | $2M | $2M | $2M | $2M | |
| Prepaid Expense | $7M | $7M | $6M | $7M | $6M | $4M | $3M | $1M | $1M | $1M | $1M | $3M | $2M | $2M | $2M | $2M | |
| Current Assets | $131M | $120M | $120M | $121M | $113M | $84M | $74M | $29M | $31M | $34M | $37M | $46M | $19M | $29M | $16M | $18M | |
| PP&E (Net) | $4M | $4M | $3M | $3M | $2M | $2M | $2M | $2M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | $1M | |
| PP&E (Gross) | $9M | $9M | $8M | $8M | $8M | $7M | $7M | $7M | $7M | $6M | $6M | $6M | $6M | $6M | $6M | $6M | |
| Accum. Depreciation | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | $5M | |
| Total Assets | $137M | $125M | $124M | $124M | $117M | $87M | $77M | $32M | $34M | $36M | $39M | $48M | $21M | $31M | $18M | $20M | |
| Accounts Payable | $4M | $3M | $3M | $2M | $5M | $2M | $961.0K | $937.0K | $3M | $1M | $1M | $753.0K | $966.0K | $2M | $2M | $3M | |
| Accrued Liabilities | $9M | $7M | $8M | $6M | $6M | $4M | $5M | $6M | $4M | $4M | $5M | $5M | $6M | $7M | $5M | $5M | |
| Current Liabilities | $13M | $11M | $11M | $8M | $10M | $5M | $6M | $22M | $12M | $13M | $16M | $14M | $11M | $13M | $15M | $14M | |
| Capital Leases | $2M | $815.0K | $835.0K | $855.0K | $877.0K | $906.0K | $933.0K | $963.0K | $989.0K | $1M | $0 | · | · | · | · | · | |
| Other Non-current Liabilities | $327.0K | $615.0K | $628.0K | $582.0K | $578.0K | $896.0K | $766.0K | $563.0K | $632.0K | $962.0K | $840.0K | $1M | $1M | $1M | $1M | $1M | |
| Total Liabilities | $16M | $12M | $12M | $9M | $12M | $7M | $8M | $23M | $30M | $21M | $23M | $23M | $21M | $25M | $24M | $25M | |
| Long-term Debt | · | · | · | · | · | · | · | $2M | $4M | $7M | $10M | · | · | · | $16M | · | |
| Common Stock | $346.0K | $344.0K | $347.0K | $353.0K | $350.0K | $334.0K | $331.0K | $280.0K | $279.0K | $254.0K | $228.0K | $197.0K | $153.0K | $101.0K | $100.0K | $86.0K | |
| Paid-in Capital | $648M | $642M | $639M | $641M | $632M | $610M | $600M | $536M | $534M | $530M | $521M | $519M | $473M | $453M | $452M | $442M | |
| Retained Earnings | $-527M | $-530M | $-529M | $-527M | $-528M | $-530M | $-532M | $-528M | $-530M | $-516M | $-505M | $-494M | $-474M | $-466M | $-457M | $-447M | |
| AOCI | $258.0K | $571.0K | $575.0K | $875.0K | $592.0K | $381.0K | $82.0K | $11.0K | $8.0K | $157.0K | $135.0K | $-59.0K | $-64.0K | $-64.0K | $-83.0K | $-57.0K | |
| Stockholders' Equity | $121M | $113M | $111M | $115M | $105M | $80M | $69M | $9M | $4M | $15M | $16M | $25M | $-242.0K | $-13M | $-6M | $-5M | |
| Liabilities + Equity | $137M | $125M | $124M | $124M | $117M | $87M | $77M | $32M | $34M | $36M | $39M | $48M | $21M | $31M | $18M | $20M | |
| Shares Outstanding | 34,636,252 | 34,465,087 | 34,691,671 | 35,308,939 | 34,955,974 | 33,436,612 | 33,061,002 | 28,019,599 | 27,931,393 | 25,439,319 | 22,761,554 | 19,688,991 | 15,250,469 | 10,046,571 | 10,046,571 | 8,597,682 |
Cashflow
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | $6M | $857.0K | $8M | $5M | $7M | $2M | $-1M | $-4M | $-4M | $-10M | $-8M | $-9M | $-10M | $-4M | $-7M | $-5M | |
| CapEx | $503.0K | $570.0K | $550.0K | $459.0K | $398.0K | $140.0K | $229.0K | $216.0K | $101.0K | $13.0K | $19.0K | $-1.0K | $40.0K | $0 | $0 | $68.0K | |
| Investing Cash Flow | $-504.0K | $-571.0K | $-561.0K | $-466.0K | $-415.0K | $-25M | $-15M | $-697.0K | $10M | $5M | $-20M | $1.0K | $-40.0K | $0 | $0 | $-68.0K | |
| Stock Issued | $0 | $389.0K | $0 | $243.0K | $0 | $238.0K | $0 | $175.0K | $0 | $75.0K | $0 | $76.0K | $0 | $47.0K | $0 | $0 | |
| Stock Repurchased | $11.0K | $3M | · | · | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| Net Stock Activity | · | $-3M | · | · | · | $238.0K | · | · | · | $75.0K | · | · | · | $47.0K | · | · | |
| Financing Cash Flow | $962.0K | $-2M | $-6M | $3M | $15M | $3M | $40M | $-2M | $-3M | $4M | $1.0K | $35M | $7.0K | $17M | $5M | $5M | |
| Net Change in Cash | $6M | $-2M | $2M | $7M | $22M | $-20M | $24M | $-6M | $3M | $-886.0K | $-28M | $26M | $-10M | $12M | $-2M | $-372.0K | |
| Taxes Paid | · | · | $228.0K | · | · | · | $0 | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | $287.0K | · | · | · | $2M | · | · | · | $-10M | · | · | · | $-4M | · | · |
Rentabilität
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 89.8% | 85.0% | · | 87.2% | 86.3% | 85.6% | · | 85.4% | 80.4% | 71.2% | · | 69.3% | 69.7% | 69.7% | · | · | |
| Operating Margin | 8.2% | -6.6% | · | -1.9% | 10.7% | 3.2% | · | -11.2% | -50.4% | -327.4% | · | -2432.3% | -1615.6% | -1394.5% | · | · | |
| Net Margin | 9.2% | -4.3% | · | 4.0% | 11.2% | 5.4% | · | 16.6% | -176.9% | -354.0% | · | -4686.6% | -1455.0% | -1507.5% | · | · | |
| Pretax Margin | 10.8% | -3.6% | · | 1.8% | 13.3% | 6.4% | · | · | · | · | · | · | · | · | · | · | |
| EBITDA Margin | 8.2% | -6.6% | · | -1.9% | 10.7% | 3.2% | · | -11.2% | -50.4% | -327.4% | · | -2432.3% | -1615.6% | -1394.5% | · | · | |
| ROA | 2.1% | -1.0% | · | 1.1% | 3.6% | 1.7% | · | 4.7% | -50.0% | -33.3% | · | -60.0% | -34.2% | -31.1% | · | -31.1% | |
| ROE | 2.4% | -1.1% | · | 1.4% | 4.9% | 2.2% | · | 11.2% | -695.8% | -1439.2% | · | -208.9% | 466.5% | 229.3% | · | -262.5% | |
| ROIC | 1.7% | -1.7% | · | -0.75% | 2.1% | 0.68% | · | · | · | · | · | · | · | · | · | · |
Liquidität & Solvenz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 9.8 | 11.2 | · | 15.1 | 10.9 | 16.0 | · | 1.3 | 2.6 | 2.5 | · | 3.3 | 1.8 | 2.2 | · | 1.3 | |
| Quick Ratio | 4.8 | 5.2 | · | 6.9 | 4.8 | 5.1 | · | 0.7 | 1.5 | 1.0 | · | 2.9 | 1.3 | 1.8 | · | 0.7 |
Effizienz
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.2 | 0.2 | · | 0.3 | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.1 | · | 0.0 | 0.0 | 0.0 | · | · | |
| Inventory Turnover | 0.3 | 0.4 | · | 0.3 | 0.4 | 0.5 | · | 0.4 | 0.3 | 0.3 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Receivables Turnover | 1.8 | 1.8 | · | 2.0 | 2.5 | 2.6 | · | 3.1 | 4.0 | 3.1 | · | 1.2 | 1.8 | 1.9 | · | · |
Pro Aktie
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $3.50 | $3.27 | · | $3.25 | $3.00 | $2.40 | · | $0.31 | $0.15 | $0.57 | · | $1.26 | $-0.02 | $-1.30 | · | $-0.61 | |
| Revenue / Share | $0.73 | $0.69 | · | $0.51 | $0.60 | $0.50 | · | $0.35 | $0.27 | $0.13 | · | $0.02 | $0.04 | $0.05 | · | · | |
| Cash Flow / Share | · | $0.02 | · | · | · | $0.06 | · | · | · | $-0.39 | · | · | · | $-0.37 | · | · | |
| Cash / Share | $1.37 | $1.20 | · | $1.18 | $0.98 | $0.38 | · | $0.30 | $0.53 | $0.46 | · | $2.06 | $0.95 | $2.41 | · | $1.14 | |
| EPS (TTM) | $0.01 | $0.01 | · | $0.06 | $0.10 | $-0.45 | · | $-1.32 | $-2.52 | $-2.62 | · | $-3.31 | $-3.13 | $-3.79 | · | $-3.95 |
Bewertung (TTM)
| Kennzahl | Trend | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $95M | $90M | · | $80M | $70M | $54M | · | $23M | $12M | $5M | · | $2M | $3M | $3M | · | · | |
| Net Income TTM | $532.0K | $561.0K | · | $1M | $2M | $-14M | · | $-34M | $-56M | $-50M | · | $-45M | $-34M | $-37M | · | $-33M | |
| Market Cap | $436M | $320M | · | $380M | $475M | $426M | · | $253M | $234M | $121M | · | $80M | $89M | $58M | · | $28M | |
| P/E | 1259.0 | 928.0 | · | 179.2 | 136.0 | -28.3 | · | -6.8 | -3.3 | -1.8 | · | -1.2 | -1.9 | -1.5 | · | -0.8 | |
| P/S | 4.6 | 3.5 | · | 4.8 | 6.8 | 7.9 | · | 11.2 | 19.7 | 26.3 | · | 36.8 | 33.7 | 19.7 | · | · | |
| P/B | 3.6 | 2.8 | · | 3.3 | 4.5 | 5.3 | · | 29.5 | 55.8 | 8.3 | · | 3.2 | -367.4 | -4.4 | · | -5.2 | |
| P / Tangible Book | 3.6 | 2.8 | · | 3.3 | 4.5 | 5.3 | · | 29.5 | 55.8 | 8.3 | · | 3.2 | · | · | · | · | |
| P / Cash Flow | · | 373.2 | · | · | · | 193.2 | · | · | · | -12.7 | · | · | · | -13.5 | · | · | |
| Earnings Yield | 0.08% | 0.11% | · | 0.56% | 0.74% | -3.5% | · | -14.6% | -30.1% | -54.9% | · | -81.7% | -53.7% | -65.9% | · | -123.4% |
Aktuellster Zeitraum links · fehlende Werte werden als · angezeigt
Finanzberichte Gewinn- und Verlustrechnung, Bilanz, Cashflow — jährlich, letzte 5 Jahre
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Umsatz | $85M | $37M | $2M | $3M | $4M |
| Bruttogewinnmarge % | 86.2% | 83.4% | 69.2% | 74.8% | · |
| Betriebsgewinnmarge % | 0.77% | -33.4% | -1849.0% | -1245.0% | · |
| Nettoergebnis | $3M | $-26M | $-48M | $-37M | $-26M |
| Verwässerte EPS | $0.07 | $-0.93 | $-2.94 | $-4.12 | $-3.59 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Liquiditätsgrad | 10.9 | 12.0 | 2.3 | 1.1 | 5.2 |
| Quick Ratio | 5.0 | 7.0 | 0.8 | 0.5 | 3.8 |
| Kennzahl | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| Freier Cashflow | $21M | $-19M | $-31M | $-25M | $-23M |
Institutionelle Eigentümer (13F) 139 Einreicher · $243.2M gesamt · Stand 30. Juni 2026
Institutionen, die diese Aktie in ihrer vierteljährlichen SEC-Formular 13F melden. Nur Long-Positionen; ein einzelner Einreicher kann für separate Optionsscheine zweimal erscheinen. Große gegenläufige Put/Call-Positionen spiegeln typischerweise Market-Making oder abgesicherte Bestände wider, nicht die gerichtete Überzeugung.
Inhaber
139
Gehaltener Wert
$243.2M
Neue Positionen
21
Geschlossene Positionen
17
Institutionelle Aktivität — Q2 2026 vs. Vorquartal
| Neue Positionen | Geschlossene Positionen | Erhöht | Abgenommen | Nettoveränderung der Aktien |
|---|---|---|---|---|
| 21 (-10 vs. Vorquartal) | 17 (-3 vs. Vorquartal) | 48 (+10 vs. Vorquartal) | 29 (-8 vs. Vorquartal) | +1.1M |
Verglichen mit Q1 2026. SEC-Formular 13F-Einreichungen sind innerhalb von 45 Tagen nach Quartalsende fällig, zuzüglich einer kurzen Pufferzeit für verspätete Einreicher — Quartale, die noch in diesem Fenster liegen, werden zugunsten des letzten vollständig berichteten Paares übersprungen.
| Institution | Wert | Aktien | % der verfolgten 13F | Typ |
|---|---|---|---|---|
| Rosalind Advisors, Inc. | $41.551.898 | 3.300.389 | 17,08% | Aktien |
| BlackRock, Inc. | $34.078.638 | 2.706.802 | 14,01% | Aktien |
| VANGUARD GROUP INC | $16.890.806 | 1.672.357 | 6,94% | Aktien |
| VANGUARD CAPITAL MANAGEMENT LLC | $15.375.500 | 1.221.247 | 6,32% | Aktien |
| Propel Bio Management, LLC | $10.971.681 | 871.460 | 4,51% | Aktien |
| GEODE CAPITAL MANAGEMENT, LLC | $9.232.592 | 733.115 | 3,80% | Aktien |
| STATE STREET CORP | $8.552.135 | 679.280 | 3,52% | Aktien |
| ALGERT GLOBAL LLC | $7.311.114 | 580.708 | 3,01% | Aktien |
| MILLENNIUM MANAGEMENT LLC | $7.130.611 | 566.371 | 2,93% | Aktien |
| Divisadero Street Capital Management, LP | $6.292.432 | 499.796 | 2,59% | Aktien |
| MORGAN STANLEY | $5.136.506 | 407.983 | 2,11% | Aktien |
| ExodusPoint Capital Management, LP | $4.530.940 | 359.884 | 1,86% | Aktien |
| Private Wealth Advisors, LLC | $3.913.765 | 310.863 | 1,61% | Aktien |
| Simplify Asset Management Inc. | $3.333.454 | 264.770 | 1,37% | Aktien |
| NORTHERN TRUST CORP | $3.174.040 | 252.108 | 1,30% | Aktien |
| GOLDMAN SACHS GROUP INC | $3.151.429 | 250.312 | 1,30% | Aktien |
| ADAR1 Capital Management, LLC | $2.825.007 | 224.385 | 1,16% | Aktien |
| MARSHALL WACE, LLP | $2.756.745 | 218.963 | 1,13% | Aktien |
| DIMENSIONAL FUND ADVISORS LP | $2.647.652 | 210.298 | 1,09% | Aktien |
| KENNEDY CAPITAL MANAGEMENT LLC | $2.570.160 | 204.143 | 1,06% | Aktien |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $2.435.510 | 193.448 | 1,00% | Aktien |
| Ikarian Capital, LLC | $2.337.548 | 185.667 | 0,96% | Aktien |
| VANGUARD FIDUCIARY TRUST CO | $2.290.159 | 181.903 | 0,94% | Aktien |
| Nuveen, LLC | $2.286.281 | 181.595 | 0,94% | Aktien |
| AQR CAPITAL MANAGEMENT LLC | $2.177.981 | 172.993 | 0,90% | Aktien |
| CIBC WORLD MARKET INC. | $2.054.789 | 163.208 | 0,84% | Aktien |
| Caption Management, LLC | $1.894.795 | 150.500 | 0,78% | Verkaufsoption |
| Lane Generational LLC | $1.884.257 | 149.663 | 0,77% | Aktien |
| HSBC HOLDINGS PLC | $1.705.848 | 135.600 | 0,70% | Aktien |
| Man Group plc | $1.617.752 | 128.495 | 0,67% | Aktien |
| Cubist Systematic Strategies, LLC | $1.562.514 | 145.350 | 0,64% | Aktien |
| Diametric Capital, LP | $1.546.568 | 122.841 | 0,64% | Aktien |
| Bank of New York Mellon Corp | $1.361.725 | 108.159 | 0,56% | Aktien |
| BARCLAYS PLC | $1.359.090 | 107.950 | 0,56% | Aktien |
| Caption Management, LLC | $1.259.000 | 100.000 | 0,52% | Kaufoption |
| Capital Advisors Wealth Management, LLC | $1.170.870 | 93.000 | 0,48% | Aktien |
| Jump Financial, LLC | $1.108.360 | 88.035 | 0,46% | Aktien |
| Jefferies Financial Group Inc. | $1.057.308 | 83.980 | 0,43% | Aktien |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $1.050.824 | 83.465 | 0,43% | Aktien |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1.022.308 | 81.200 | 0,42% | Kaufoption |
| Stonepine Capital Management, LLC | $1.000.000 | 100.000 | 0,41% | Kaufoption |
| Caption Management, LLC | $978.243 | 77.700 | 0,40% | Aktien |
| Russell Investments Group, Ltd. | $851.813 | 67.658 | 0,35% | Aktien |
| FOX RUN MANAGEMENT, L.L.C. | $776.526 | 61.678 | 0,32% | Aktien |
| BANK OF AMERICA CORP /DE/ | $774.587 | 61.524 | 0,32% | Aktien |
| Quantbot Technologies LP | $749.860 | 59.560 | 0,31% | Aktien |
| D. E. Shaw & Co., Inc. | $728.885 | 57.894 | 0,30% | Aktien |
| BNP PARIBAS FINANCIAL MARKETS | $725.864 | 57.654 | 0,30% | Aktien |
| Creative Planning | $609.784 | 48.434 | 0,25% | Aktien |
| UBS Group AG | $525.179 | 41.714 | 0,22% | Aktien |
Aktivisten & 5%+-Eigentümer 17 Beteiligungen
Investoren mit SEC Schedule 13D — wirtschaftliches Eigentum über 5% mit der Absicht, Einfluss auf den Emittenten zu nehmen (aktivistische Beteiligungen, Board-Kampagnen, M&A). Jede Zeile zeigt den zuletzt bekannten Stand der Position dieses Melders.
| Anmelder | Eingereicht | Beteiligung | Status | Zweck | Einreichung |
|---|---|---|---|---|---|
| Rosalind Advisors, Inc., SALAMON STEVEN A J, Aharon Gil, Rosalind Master Fund L.P., Rosalind Opportunities Fund I L.P. ×15 Einreichungen | 10. Februar 2026 | 9,90% | Änderung | · | SEC |
| Nicht offengelegter meldender Beteiligter | 16. Dezember 2022 | · | Erste Einreichung | Passive Anlage | SEC |
| Nicht offengelegter meldender Beteiligter | 27. Juli 2022 | · | Erste Einreichung | Passive Anlage | SEC |
| Laddcap Value Partners LP S.S. or, Laddcap Value Associates LLC S.S. or, Laddcap Value Advisors LLC S.S. or, Robert Ladd S.S. or ×2 Einreichungen | 2. August 2010 | · | Erste Einreichung | · | SEC |
| Robert Ladd | 18. Oktober 2006 | · | Erste Einreichung | Passive Anlage | SEC |
| Nicht offengelegter meldender Beteiligter | 28. Juli 2006 | · | Erste Einreichung | Vorstandskampagne | SEC |
| Nicht offengelegter meldender Beteiligter | 11. Juli 2006 | · | Erste Einreichung | · | SEC |
| Nicht offengelegter meldender Beteiligter | 14. Juni 2006 | · | Erste Einreichung | · | SEC |
| Nicht offengelegter meldender Beteiligter | 8. Juni 2006 | · | Erste Einreichung | · | SEC |
| Nicht offengelegter meldender Beteiligter | 24. Mai 2006 | · | Erste Einreichung | · | SEC |
| Nicht offengelegter meldender Beteiligter | 28. April 2006 | · | Erste Einreichung | · | SEC |
| Nicht offengelegter meldender Beteiligter | 10. Januar 2006 | · | Erste Einreichung | · | SEC |
| Nicht offengelegter meldender Beteiligter | 6. Januar 2006 | · | Erste Einreichung | · | SEC |
| Nicht offengelegter meldender Beteiligter | 14. Dezember 2005 | · | Erste Einreichung | · | SEC |
| Nicht offengelegter meldender Beteiligter | 10. November 2005 | · | Erste Einreichung | Vorstandskampagne | SEC |
| Nicht offengelegter meldender Beteiligter | 24. Oktober 2005 | · | Erste Einreichung | · | SEC |
| Nicht offengelegter meldender Beteiligter | 17. Oktober 2005 | · | Erste Einreichung | Passive Anlage | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
Unternehmensinsider 49 Insider · 13 Führungskräfte · 17 Direktoren
| Insider | Rolle | Letzte Aktivität | Gehaltene Aktien | Käufe 12m | Verkäufe 12m | Netto 12m |
|---|---|---|---|---|---|---|
| Jennifer K. Simpson | President and CEO | 8. Mai 2020 C | 25.021 | 0 | 0 | $0 |
| Sandra Pennell | Chief Financial Officer | 6. März 2026 P | 77.018 | 1 | 0 | $50.018 |
| Barbra Keck | Chief Financial Officer, Secretary | 8. Mai 2020 C | 12.851 | 0 | 0 | $0 |
| Paul M Feinstein | Chief Financial Officer | 30. November 2007 A | 3.375 | 0 | 0 | $0 |
| Martha S. Rook | CHIEF OPERATING OFFICER | 17. Februar 2026 A | · | 0 | 0 | $0 |
| John Purpura | CHIEF OPERATING OFFICER | 8. Februar 2023 A | 41.526 | 0 | 0 | $0 |
| HERSCHKOWITZ SAMUEL /FA/ | Chief Operating Officer | 29. Mai 2007 P | 160.375 | 0 | 0 | $0 |
| David L. Hoffman | GEN'L COUNSEL, CCO & SECY | 17. Februar 2026 A | 74.330 | 0 | 0 | $0 |
| Kevin Muir | GM INTERVENTIONAL ONCOLOGY | 17. Februar 2026 A | 18.582 | 0 | 0 | $0 |
| Vojo Vukovic | CHIEF MEDICAL OFFICER | 17. Februar 2026 A | 168.882 | 0 | 0 | $0 |
| Johnny John | SVP CLINICAL DEV & MED AFFAIRS | 8. Februar 2023 A | · | 0 | 0 | $0 |
| Anthony Dias | VP FINANCE | 8. Februar 2023 A | · | 0 | 0 | $0 |
| Christine Padula | Interim Principal Accounting Officer | 1. September 2021 A | · | 0 | 0 | $0 |
| Aharon Gil | Direktor | 13. Mai 2026 A | 3.413.468 | 0 | 0 | $0 |
| John Richard Sylvester | Direktor | 13. Mai 2026 A | 14.936 | 1 | 0 | $38.992 |
| Bridget A Martell | Direktor | 13. Mai 2026 A | · | 0 | 0 | $0 |
| Steven A J Salamon | Direktor | 13. Mai 2026 A | 3.413.468 | 0 | 0 | $0 |
| Roger G Stoll PHD | Direktor | 23. Mai 2024 A | 9.309 | 0 | 0 | $0 |
| Rosalind Advisors, Inc. | Direktor | 14. Dezember 2022 P | 459.315 | 0 | 0 | $0 |
| Marco Taglietti | Direktor | 8. Mai 2020 C | 6.000 | 0 | 0 | $0 |
| William Dodge Rueckert | Direktor | 8. Mai 2020 C | 6.014 | 0 | 0 | $0 |
| Simon Pedder | Direktor | 1. Februar 2019 A | · | 0 | 0 | $0 |
| Laura A Philips | Direktor | 23. Juli 2015 P | 205.299 | 0 | 0 | $0 |
| Harold S Koplewicz | Direktor | 10. Juni 2015 A | 45.052 | 0 | 0 | $0 |
| Dennis Langer | Direktor | 10. Juni 2015 A | 20.000 | 0 | 0 | $0 |
| Jonathan Lewis | Direktor | 30. Juni 2008 A | 10.000 | 0 | 0 | $0 |
| Mark Corigliano | Direktor | 16. April 2007 M | 198.176 | 0 | 0 | $0 |
| Daniel Isdaner | Direktor | 16. April 2007 M | 253.668 | 0 | 0 | $0 |
| Elizabeth Czerepak | · | 13. Mai 2026 A | · | 0 | 0 | $0 |
| Gerard J Michel | · | 2. März 2026 P | 342.034 | 2 | 0 | $198.447 |
| Laura Brege | · | 7. Juli 2014 A | 11.678 | 0 | 0 | $0 |
| Tasos Konidaris | · | 7. Juli 2014 A | 11.678 | 0 | 0 | $0 |
| Gabriel Leung | · | 7. Juli 2014 A | 21.485 | 0 | 0 | $0 |
| Douglas G Watson | · | 7. Juli 2014 A | 136.664 | 0 | 0 | $0 |
| Graham G Miao | · | 14. November 2013 A | 54.000 | 0 | 0 | $0 |
| Peter J Graham | · | 14. November 2013 A | 15.000 | 0 | 0 | $0 |
| William M Appling | · | 15. Juli 2013 A | · | 0 | 0 | $0 |
| Krishna Kandarpa | · | 11. März 2013 A | 159.000 | 0 | 0 | $0 |
| Harold Mapes | · | 11. März 2013 A | 17.000 | 0 | 0 | $0 |
| Eamonn P Hobbs | · | 11. März 2013 A | 162.000 | 0 | 0 | $0 |
| Agustin V Gago | · | 11. März 2013 A | 80.944 | 0 | 0 | $0 |
| Robert Ladd | · | 15. Juni 2012 A | 69.534 | 0 | 0 | $0 |
| David Mcdonald | · | 10. März 2011 A | 47.706 | 0 | 0 | $0 |
| Pamela Reilly Contag | · | 1. Dezember 2010 A | 8.507 | 0 | 0 | $0 |
| Richard Taney | · | 10. Dezember 2009 A | 211.485 | 0 | 0 | $0 |
| Jason Andrew Rifkin | · | 12. Oktober 2009 A | · | 0 | 0 | $0 |
| KOLY M S /FA/ | · | 26. Januar 2007 X | 775.360 | 0 | 0 | $0 |
| Victor Nevins | · | 12. Oktober 2006 M | 180.007 | 0 | 0 | $0 |
| VENKOL TRUST | · | 10. November 2004 J | 892.649 | 0 | 0 | $0 |
Insider aus SEC-Einreichungen Form 3/4/5; Netto = nur P/S aus offenen Märkten
ETF-Besitz Gehalten von 16 ETFs
Gewichtung spiegelt nur direkte Aktienbestände (N-PORT) wider; gehebelte oder derivatbasierte Fonds können zusätzliche Swap-Exposure halten, die hier nicht angezeigt wird.
| Fonds | Gewicht | Anteile | Stand | Quelle |
|---|---|---|---|---|
| IWC · iShares Trust | 0,11% | 97.206 SH | 11. September 2026 | Täglich |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0,02% | 21.358 SH | 19. August 2026 | Täglich |
| IWM · iShares Trust | 0,02% | 743.359 SH | 11. September 2026 | Täglich |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0,01% | 2.376 SH | 2. Oktober 2026 | Täglich |
| RSSL · Global X Funds | 0,01% | 13.736 NS | 31. Juli 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0,01% | 165.177 SH | 19. August 2026 | Täglich |
| DFAS · Dimensional ETF Trust | 0,01% | 70.373 NS | 31. Juli 2026 | N-PORT |
| IWO · iShares Trust | 0,00% | 39.522 SH | 11. September 2026 | Täglich |
| DFSU · Dimensional ETF Trust | 0,00% | 3.297 NS | 31. Juli 2026 | N-PORT |
| ITOT · iShares Trust | 0,00% | 43.746 SH | 11. September 2026 | Täglich |
| DFAC · Dimensional ETF Trust | 0,00% | 12.489 NS | 31. Juli 2026 | N-PORT |
| VXF · VANGUARD INDEX FUNDS | 0,00% | 304.809 SH | 19. August 2026 | Täglich |
| VTI · VANGUARD INDEX FUNDS | 0,00% | 889.410 SH | 19. August 2026 | Täglich |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0,00% | 4.438 SH | 19. August 2026 | Täglich |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0,00% | 2.475 SH | 19. August 2026 | Täglich |
| IWN · iShares Trust | · | 228.409 SH | 11. September 2026 | Täglich |
DCTH Analysten-Konsens Bullische und bärische Analystenmeinungen, 12-Monats-Kursziel, Aufwärtspotenzial
Bewertung · 12 Analysten
KAUF
Median-Ziel
$22.00
+45,4%
3 25,0%
Starker Kauf
8 66,7%
Kauf
1 8,3%
Halten
0 0,0%
Verkauf
0 0,0%
Starker Verkauf
12-Monats-Kursziel
5 Analysten · 2026-09-29Mittelwert-Ziel $24.00 +58,6%
← Unter allen Zielen
Aktueller Preis $15.13
Tief$21.00
Mittelwert$24.00
Hoch$32.00
Peer-Vergleich (GICS-Subbranche) Wichtige Kennzahlen im Vergleich zu Branchenkollegen
FY-Basis, Kurse zum Schlusskurs am Ende des letzten Geschäftsjahres jedes Unternehmens.
| Ticker | Marktkapitalisierung | P/E | Umsatz Vj. | Nettomarge | ROE | Bruttogewinnmarge |
|---|---|---|---|---|---|---|
| DCTH | $350M | 144.3 | 129.1% | 3.2% | 2.5% | 86.2% |
| SSII | · | -94.7 | 105.7% | · | · | · |
| SENS | $228M | -3.3 | 56.9% | -196.0% | -88.7% | 44.7% |
| TCMD | $651M | 35.4 | 12.5% | 5.8% | 9.2% | 75.9% |
| SGHT | $424M | -10.7 | -3.1% | -49.7% | -57.4% | 86.2% |
| NPCE | $518M | -23.4 | 25.1% | -21.5% | -111.6% | 77.2% |
| SI | $295M | -3.1 | 49.6% | -85.3% | -129.1% | 76.5% |
| CARL | $329M | -5.8 | 85.9% | -58.7% | -375.2% | 75.3% |
| OFIX | $604M | -6.5 | 2.9% | -11.2% | -20.3% | 68.8% |
| ABT | $250.18B | 33.7 | 5.7% | 14.7% | 13.1% | · |
Meine Kennzahlen Ihre persönliche Watchlist — ausgewählte Zeilen aus den vollständigen Fundamentaldaten
Wählen Sie die Kennzahlen, die für Sie wichtig sind — klicken Sie auf das + neben jeder Zeile in den vollständigen Fundamentaldaten oben.
Ihre Auswahl wird gespeichert und begleitet Sie über alle Ticker hinweg.
Quelle: SEC 10-Q eingereicht Aug 6, 2026